|
1
|
Calderaro J, Seraphin TP, Luedde T and
Simon TG: Artificial intelligence for the prevention and clinical
management of hepatocellular carcinoma. J Hepatol. 76:1348–1361.
2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zheng RS, Chen R, Han BF, Wang SM, Li L,
Sun KX, Zeng HM, Wei WW and He J: Cancer incidence and mortality in
China, 2022. Zhonghua Zhong Liu Za Zhi (Chinese). 46:221–231.
2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Qiu F, Qiu F, Liu L, Liu J, Xu J and Huang
X: The role of dermcidin in the diagnosis and staging of
hepatocellular carcinoma. Genet Test Mol Biomarkers. 22:218–223.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Urquijo-Ponce JJ, Alventosa-Mateu C,
Latorre-Sánchez M, Castelló-Miralles I and Diago M: Present and
future of new systemic therapies for early and intermediate stages
of hepatocellular carcinoma. World J Gastroenterol. 30:2512–2522.
2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hoti E and Adam R: Liver transplantation
for primary and metastatic liver cancers. Transpl Int.
21:1107–1117. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sapisochin G and Bruix J: Liver
transplantation for hepatocellular carcinoma: outcomes and novel
surgical approaches. Nat Rev Gastroenterol Hepatol. 14:203–217.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Neuberger J: An update on liver
transplantation: A critical review. J Autoimmun. 66:51–59.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gao S, Gang J, Yu M, Xin G and Tan H:
Computational analysis for identification of early diagnostic
biomarkers and prognostic biomarkers of liver cancer based on GEO
and TCGA databases and studies on pathways and biological functions
affecting the survival time of liver cancer. BMC Cancer.
21(791)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fabregat I: Dysregulation of apoptosis in
hepatocellular carcinoma cells. World J Gastroenterol. 15:513–520.
2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Li X, Li X, Hu Y, Liu O, Wang Y, Li S,
Yang Q and Lin B: PSMD8 can serve as potential biomarker and
therapeutic target of the PSMD family in ovarian cancer: based on
bioinformatics analysis and in vitro validation. BMC Cancer.
23(573)2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Jiang L, Qi X, Lai M, Zhou J, Yuan M, You
J, Liu Q, Pan J, Zhao L, Ying M, et al: WDR20 prevents
hepatocellular carcinoma senescence by orchestrating the
simultaneous USP12/46-mediated deubiquitination of c-Myc. Proc Natl
Acad Sci USA. 121(e2407904121)2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wang M, Yu F and Li P: Intratumor
microbiota in cancer pathogenesis and immunity: From mechanisms of
action to therapeutic opportunities. Front Immunol.
14(1269054)2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Li H, Ji Z, Paulo JA, Gygi SP and Rapoport
TA: Bidirectional substrate shuttling between the 26S proteasome
and the Cdc48 ATPase promotes protein degradation. Mol Cell.
84:1290–1303.e7. 2024.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Coll-Martínez B and Crosas B: How the 26S
proteasome degrades ubiquitinated proteins in the cell.
biomolecules. 9(395)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Xuan DTM, Wu CC, Kao TJ, Ta HDK, Anuraga
G, Andriani V, Athoillah M, Chiao CC, Wu YF, Lee KH, et al:
Prognostic and immune infiltration signatures of proteasome 26S
subunit, non-ATPase (PSMD) family genes in breast cancer patients.
Aging (Albany NY). 13:24882–24913. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li Y, Liu X, Zhao F, Zhao Z, Li X, Wang J,
Huang B and Chen A: Comprehensive analysis of PSMD family members
and validation of PSMD9 as a potential therapeutic target in human
glioblastoma. CNS Neurosci Ther. 30(e14366)2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang C, Xu T, Ji K, Cao S, Cao Y, Ai J,
Jing L and Sun JH: An integrative analysis reveals the prognostic
value and potential functions of PSMD11 in hepatocellular
carcinoma. Mol Carcinog. 62:1355–1368. 2023.PubMed/NCBI View
Article : Google Scholar
|
|
18
|
Huang W, Mei J, Liu YJ, Li JP, Zou X, Qian
XP and Zhang Y: An analysis regarding the association between
proteasome (PSM) and hepatocellular carcinoma (HCC). J Hepatocell
Carcinoma. 10:497–515. 2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tsolou A, Nelson G, Trachana V,
Chondrogianni N, Saretzki G, von Zglinicki T and Gonos ES: The 19S
proteasome subunit Rpn7 stabilizes DNA damage foci upon genotoxic
insult. IUBMB Life. 64:432–442. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Han B, Zheng R, Zeng H, Wang S, Sun K,
Chen R, Li L, Wei W and He J: Cancer incidence and mortality in
China, 2022. J Natl Cancer Cent. 4:47–53. 2024.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Valery PC, Laversanne M, Clark PJ, Petrick
JL, McGlynn KA and Bray F: Projections of primary liver cancer to
2030 in 30 countries worldwide. Hepatology. 67:600–611.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Singal AG, Kanwal F and Llovet JM: Global
trends in hepatocellular carcinoma epidemiology: Implications for
screening, prevention and therapy. Nat Rev Clin Oncol. 20:864–884.
2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhao K, Zhou X, Xiao Y, Wang Y and Wen L:
Research progress in alpha-fetoprotein-induced immunosuppression of
liver cancer. Mini Rev Med Chem. 22:2237–2243. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhou SS, Ye YP, Chen Y, Zeng DT, Zheng GC,
He RQ, Chi BT, Wang L, Lin Q, Su QY, et al: Overexpression pattern,
function, and clinical value of proteasome 26S subunit non-ATPase 6
in hepatocellular carcinoma. World J Clin Oncol.
16(99839)2025.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhou C, Li H, Han X, Pang H, Wu M, Tang Y
and Luo X: Prognostic value and molecular mechanisms of proteasome
26S subunit, non-ATPase family genes for pancreatic ductal
adenocarcinoma patients after pancreaticoduodenectomy. J Invest
Surg. 35:330–346. 2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Guedes RA, Serra P, Salvador JA and Guedes
RC: Computational approaches for the discovery of human proteasome
inhibitors: An overview. Molecules. 21(927)2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zong Q, Mao B, Zhang HB, Wang B, Yu WJ,
Wang ZW and Wang YF: Comparative Ubiquitome analysis reveals
deubiquitinating effects induced by Wolbachia infection in
drosophila melanogaster. Int J Mol Sci. 23(9459)2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Donne R and Lujambio A: The liver cancer
immune microenvironment: Therapeutic implications for
hepatocellular carcinoma. Hepatology. 77:1773–1796. 2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ruff SM, Shannon AH, Beane JD and Pawlik
TM: Highlighting novel targets in immunotherapy for liver cancer.
Expert Rev Gastroenterol Hepatol. 16:1029–1041. 2022.PubMed/NCBI View Article : Google Scholar
|
